Does mindfulness-based cognitive therapy with tapering support reduce risk of relapse/recurrence in major depressive disorder by enhancing positive affect? A secondary analysis of the PREVENT trial.
Journal of consulting and clinical psychology September 1, 2024 Barnaby D Dunn, Laura Warbrick, Rachel Hayes et al. 10 citations
Mindfulness-based cognitive therapy with support to taper medication (MBCT-TS) increases positive affect more than continuing antidepressant medication alone, and this increase partly explains the reduced risk of relapse or recurrence in people with recurrent depression. In a randomized trial of 424 adults with three or more prior depressive episodes, MBCT-TS led to significantly greater positive affect at posttreatment compared with maintenance antidepressants. Across both treatments, higher positive affect at intake predicted a lower hazard of relapse over two years. Among participants who had not relapsed by posttreatment, a greater rise in positive affect mediated a reduced risk of subsequent relapse. The findings indicate that boosting positive affect is one mechanism through which MBCT-TS protects against relapse when discontinuing antidepressants.